Moderna, Merck breakthrough could usher in wave of cancer vaccines
The treatment involves pairing Merck's immunotherapy drug with a customized mRNA vaccine that instructs the immune system to attack specific cancer cells.
Merck and Moderna have developed a groundbreaking personalized cancer vaccine that could revolutionize the treatment of melanoma, according to recent trials. The vaccine, designed to target specific mutations present in a patient's tumor, aims to prevent the recurrence and spread of the disease, unlike traditional chemotherapy or immunotherapy treatments.
In a large-scale trial involving over 1,000 melanoma patients, the vaccine showed promising results in keeping the cancer at bay. Merck and Moderna anticipate that thousands of melanoma patients could benefit from this new treatment within the first few years of its approval. However, the current subscription plan does not permit commenting on this story.
Written by urgent.news from Japan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Promising Results for mRNA Cancer Vaccine from Moderna and Merck time.com
- Moderna and Merck shares soar on mRNA cancer vaccine axios.com
- How Moderna's melanoma mRNA vaccine could fight deadliest skin cancer cbsnews.com
- Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck seekingalpha.com
